Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $469.55, marking a +1.15% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.32%.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the ...

Vertex (VERX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Vertex holds a monopoly position in cystic fibrosis with the blockbuster drug Trikafta which is its main growth driver most likely until 2037. While the stock significantly underperformed the S&P ...

Biotech company Vertex Pharmaceuticals (VRTX 1.56%) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 ...

Let's look at one biotech stock, Vertex Pharmaceuticals (VRTX-0.62%), and determine whether it falls in the first or the second category. Can this biotech giant help investors retire with $1 ...